Last reviewed · How we verify
other causes of cognitive decline — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Neuraceq | FLORBETABEN | Life Molecular | Radioactive Diagnostic Agent [EPC] | 2025-01-01 | ||
| Vizamyl | FLUTEMETAMOL | Ge Healthcare | Radioactive Diagnostic Agent [EPC] | 2013-01-01 | ||
| Amyvid | FLORBETAPIR | Avid Radiopharms Inc | Radioactive Diagnostic Agent [EPC] | 2013-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Avid Radiopharms Inc · 1 drug in other causes of cognitive decline
- Ge Healthcare · 1 drug in other causes of cognitive decline
- Life Molecular · 1 drug in other causes of cognitive decline
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in other causes of cognitive decline:
- other causes of cognitive decline treatment updates — RSS
- other causes of cognitive decline treatment updates — Atom
- other causes of cognitive decline treatment updates — JSON
Cite this brief
Drug Landscape (2026). other causes of cognitive decline — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/other-causes-of-cognitive-decline. Accessed 2026-06-10.
Related
- other causes of cognitive decline full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing